Susanna Fletcher Greer, Chief Scientific Officer at the V Foundation, shared on LinkedIn:
“Some of the most challenging cancers strike children and teenagers. Ewing sarcoma and osteosarcoma are cancers of the bones and soft tissues that can be especially difficult to treat when they spread or return. For Ewing sarcoma, fewer than 30% of patients with metastatic or recurrent disease survive five years. We desperately need better options for these young patients.
One promising approach involves taking a patient’s own immune cells and engineering them to recognize and attack cancer. These specially modified cells, called CAR T cells, have transformed treatment for certain blood cancers. But solid tumors present a frustrating challenge. The immune cells need something recognizable on the cancer cell to attack it. And tumors don’t always cooperate.
One potential target is a molecule called GD2, found on the surface of some cancer cells. Unfortunately, Ewing sarcoma and osteosarcoma cells often display too little GD2, or display it unevenly, allowing cancer cells to escape recognition. So the V Foundation grantee Dr. Ian Davis and colleagues at UNC Lineberger Comprehensive Cancer Center asked this question:
What if we could make the cancer cells reveal themselves?

The team combined two drugs that change how genes are regulated, essentially encouraging tumor cells to display more GD2 on their surfaces. And it worked!
The combination made cancer cells more recognizable to CAR T cells. In two mouse models of Ewing sarcoma, this approach improved tumor control, with some mice remaining free of detectable disease at the end of the experiments. This is a cool approach and it challenges how I think about immunotherapy. As in, rather than only making immune cells better at attacking cancer, what if we could also make cancer more vulnerable to attack?
For children and families facing these difficult cancers, discoveries like this open exciting possibilities for making powerful immunotherapies work against tumors that have resisted them. So in this case, the breakthrough isn’t finding a stronger weapon, it’s finding a way to make cancer stop hiding.
Find the paper and visit the Davis lab at Meet our Team!”
Title: GD2 Induction by Combination Chromatin-Directed Inhibitors Enhances Targeting of Ewing Sarcoma and Osteosarcoma by CAR T Cells
Authors: Justin R. Sperlazza, Kevin C. Field, Caitlyn McComb, Elisa Landoni, Sara K. Peterson, Anna Jin, Austin J. Hepperla, Rachel L. Chambers, William C. Zamboni, Barbara Savoldo, Ian J. Davis
Read the Full Article on Molecular Cancer Therapeutics
You can also read:
How Lewis Hamilton and F1 Helped Raise £275K for Childhood Cancer Research
Sarcoma at Nineteen: Why Treating Young Adults Is Different
Bone Cancer Treatment Success Rate: What Patients Should Know